Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,262 across all filing types
Latest filing 2022-08-23 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
2022年员工持股计划（草案）
Capital/Financing Update Classification · 95% confidence The document is a detailed draft of an employee stock ownership plan (员工持股计划草案) for the year 2022 by the company 葵花药业集团股份有限公司. It includes comprehensive information about the plan's purpose, principles, participants, scale, stock source, funding, pricing, duration, lock-up periods, management structure, changes, termination, and rights of participants. The document references relevant laws and regulations and is quite lengthy (15,000 characters). It is not a brief announcement or a simple notification but a full plan document. This type of document is a detailed plan related to capital structure and employee shareholding, which fits best under the category of Capital/Financing Update (CAP), as it concerns the company's financing activities through employee stock ownership plans and share repurchases for this purpose. It is not an Annual Report, Earnings Release, or Management Report, nor is it a regulatory filing or announcement. Therefore, the most appropriate classification is CAP with high confidence.
2022-08-23 Chinese
关于公司2022年员工持股计划（草案）是否符合《关于上市公司实施员工持股计划试点的指导意见》相关规定的说明
Regulatory Filings Classification · 95% confidence The document is a statement from the board of directors regarding the compliance of the company's 2022 employee stock ownership plan with relevant regulatory guidelines and laws. It discusses legal compliance, board and supervisory verification, and the rationale for the plan. There is no financial data, no report of financial results, no voting results, no announcement of a report publication, and no mention of a meeting or shareholder vote. The document is a regulatory compliance statement related to an employee stock ownership plan, which does not fit into categories like Annual Report, Earnings Release, or Capital/Financing Update. It is not a proxy solicitation or remuneration report either. Given the nature of the content and the absence of other specific categories, the best fit is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and compliance documents.
2022-08-23 Chinese
2022年员工持股计划管理办法
Governance Information Classification · 95% confidence The document is titled as the "2022 Employee Stock Ownership Plan Management Measures" of a company, detailing the principles, implementation, management, and procedures of an employee stock ownership plan. It includes legal references, stock quantities, lock-up periods, performance assessments, management committees, and shareholder meeting procedures related to the employee stock ownership plan. There is no indication that this is a financial report, earnings release, or regulatory announcement. Instead, it is a detailed governance and management document about the employee stock ownership plan, which is a governance-related internal policy document. Therefore, the most appropriate classification is Governance Information (CGR). The document length is substantial and contains detailed rules and procedures, not just an announcement or summary, so it is not an RPA or RNS.
2022-08-23 Chinese
独立董事关于第四届董事会第二十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters related to the company's employee stock ownership plan discussed at the 21st meeting of the 4th board. It references compliance with company law, stock exchange rules, and internal governance. The document is a formal opinion letter from independent directors rather than a full report or announcement of financial results. It does not contain financial statements or earnings data, nor is it a regulatory filing or announcement of voting results. It is related to board/management information as it concerns board meeting decisions and governance matters regarding employee stock plans.
2022-08-23 Chinese
第四届监事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 14th meeting of the 4th Supervisory Board of the company. It discusses the review and approval of the 2022 Employee Stock Ownership Plan (ESOP) draft and management measures. The document includes statements about compliance with relevant laws and regulations, the process of the meeting, and the submission of unresolved matters to the shareholders' meeting. There are no financial statements or detailed financial data presented. The document is an official announcement of board/management decisions related to employee stock plans, which fits best under Board/Management Information (MANG). The document length is short (1864 characters), and it is not a report or a presentation but a meeting resolution announcement.
2022-08-23 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Audit Report / Information Classification · 90% confidence The document is a special statement and independent opinion by the independent directors of a company regarding the use of company funds by controlling shareholders and related parties, as well as the company's external guarantees. It references compliance with company law, stock exchange listing rules, and internal control systems. The content focuses on governance and compliance matters rather than financial results or audit opinions. It is not a full audit report, annual report, or financial statement. The document is relatively short (496 characters) and is a formal statement by independent directors, which aligns with governance or regulatory compliance disclosures. Given the nature of the content and the regulatory references, this fits best under Audit Report / Information (AR), as it is a standalone report on specific governance and financial control issues, not a full annual report or other category. H1 2022
2022-08-09 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.